PainReform Ltd.
(PRFX)
Add Watchlist
0.85 USD -0.04
Closed: 17 May, 3:50 pm
Symbol PRFX
Market Cap 2M
Price 0.85
Open 0.80
52-wk High 26.41
50 Day Avg 1.34
Earnings Announcement 2024-08-08
Website https://www.painreform.com
Name PainReform Ltd.
Shares Outstanding 2,473,740
Change % 0.7747%
Low 0.80
52-wk Low 0.42
200 Day Avg 2.63
Last Dividend 0.00
Exchange NASDAQ
Volume 37,643
Previous Close 0.84
High 0.87
EPS -7.14
PE -0.12
Avg Volume 147,467
CUSIP M77798102
PainReform Ltd. Outlook
Description PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
Currency USD
ISIN IL0011651580
Industry Drug Manufacturers - Specialty & Generic
Changes 0.01
CUSIP M77798102
Range 0.42 - 26.41
Beta 0.73
CIK 0001801834

PainReform Ltd. News

15-May-2024 4:05 PM

PainReform Provides Business Update for the First Quarter of 2024

Reaches 50% e nrollment in the s econd p art of its Phase 3 c linical t rial of PRF-110 in b unionectomy

08-May-2024 8:30 AM

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, participated in an interview with Proactiveinvestors.com.

18-Apr-2024 2:19 PM

PainReform Announces Closing of $4 Million Public Offering

TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the closing of its previously announced public offering of an aggregate of 5,000,000 of the Company's ordinary shares (or ordinary share equivalents) and warrants to purchase up to 5,000,000 ordinary shares at a combined public offering price of $0.80 per share (or per ordinary share equivalent) and accompanying warrant. The warrants have an exercise price of $0.80 per share, are exercisable immediately upon issuance and will expire five years from the date of issuance.

09-Apr-2024 9:00 AM

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

TEL AVIV, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced groundbreaking results from new studies demonstrating the superior in-vitro release (IVR) rates of PRF-110 compared to the industry leader for topical post-surgical pain management products. These findings underscore PainReform's commitment to advancing non-opiate pain relief options and mark a significant milestone in the development of long-lasting pain management solutions.

02-Apr-2024 8:30 AM

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it has reached the 50% enrollment target for the second part of Phase 3 clinical trial of PRF-110 in bunionectomy.

01-Mar-2024 8:00 AM

PainReform Provides Year-End Business Update

Reports continued enrollment in the second part of the Phase 3 clinical trial in bunionectomy

22-Jan-2024 8:30 AM

PainReform to Present at the Microcap Conference in Atlantic City

TEL AVIV, Israel, Jan. 22, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. ( Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that management will be participating at The Microcap Conference which is being held on January 30 - February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ.

22-Jan-2024 8:30 AM

PainReform to Present at the Microcap Conference in Atlantic City

Tel Aviv, Israel--(Newsfile Corp. - January 22, 2024) - PainReform Ltd. (NASDAQ: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that management will be participating at The Microcap Conference which is being held on January 30 - February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ.

03-Jan-2024 8:30 AM

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading

26-Dec-2023 6:00 PM

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

TEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 467,896 ordinary shares, having an exercise price of $9.00 per ordinary share, issued by PainReform in July 2023, at a reduced exercise price of $2.85 per ordinary share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form F-1 (File No. 333-274220). The closing of the offering is expected to occur on or about December 29, 2023, subject to satisfaction of customary closing conditions.

15-Nov-2023 4:05 PM

PainReform Provides Business Update for the Third Quarter of 2023

Reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomy Reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomy